BCIQ Profiles

Company Profile Report

Prima reports response data from Phase IIb of IMP321 in breast cancer

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) reported additional data from 15 evaluable patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb

Read the full 279 word article

How to gain access

Continue reading with a
two-week free trial.